Angelica Spolzino
A5076399497- Fungal Infections and Studies
- Antifungal resistance and susceptibility
- Neutropenia and Cancer Infections
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Acute Lymphoblastic Leukemia research
- Viral-associated cancers and disorders
- Hematological disorders and diagnostics
- Infectious Diseases and Mycology
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Gut microbiota and health
- Blood disorders and treatments
- CAR-T cell therapy research
- Renal Diseases and Glomerulopathies
- Anorectal Disease Treatments and Outcomes
- Complement system in diseases
- Calcium signaling and nucleotide metabolism
- Mycobacterium research and diagnosis
- Immune Cell Function and Interaction
- Autophagy in Disease and Therapy
- Pediatric health and respiratory diseases
- Ocular Infections and Treatments
- Leprosy Research and Treatment
- Bipolar Disorder and Treatment
University of Parma
2013-2024
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2023-2024
Istituto Oncologico Veneto
2023-2024
Ospedale di Parma
2019-2023
Ege University
2022
Sapienza University of Rome
2020
Ospedale Maggiore
2016
Human mesenchymal stem cells (hMSCs) are pluripotent adult capable of being differentiated into osteoblasts, adipocytes, and chondrocytes. The osteogenic differentiation hMSCs is regulated either by systemic hormones or local growth factors able to induce specific intracellular signal pathways that modify the expression activity several transcription factors. Runt-related factor 2 (Runx2) Wnt signaling-related molecules major critically involved in process hMSCs, SRY-related...
Bloodstream infections (BSI) caused by Gram-negative bacteria (GNB) in patients with hematological malignancies (HM) have been associated high mortality rates, particularly antibiotic-resistant strains. A multicenter cohort study including all consecutive episodes of GNB BSI HM was conducted to update the epidemiology and antibiotic resistance patterns (compared our previous survey between 2009 2012) investigate risk factors for due multidrug-resistant (MDR) isolates. total 834 were...
Bloodstream infections (BSIs) remain life-threatening complications in the clinical course of patients with haematological malignancies (HM) and Escherichia coli represent one most frequent cause such infections. In this study, we aimed to describe risk factors for resistance third generation cephalosporins prognostic factors, including impact resistance, HM BSIs caused by E. coli. Three hundred forty-two cases were collected during study period (from January 2016 December 2017). The...
Hairy cell leukemia (HCL) is a rare lymphoproliferative disease with an excellent prognosis after treatment cladribine (2CDA), although relapse may occur during follow-up. The aim of the study to review efficacy, safety, long-term remission rate, and overall survival (OS) in those patients who received 2CDA as first-line treatment. We retrospectively reviewed data HCL treated between March 1991 May 2019 at 18 Italian Hematological centers: 513 were evaluable for purpose. median age was 54...
Rhodotorula spp are uncommon yeasts able to cause infections with high mortality rates. have been associated the presence of central venous catheter (CVC), immunosuppression, exposure antifungals and either solid or haematologic malignancies. However, in this latter setting, only a few cases so far reported.We conducted survey for patients.Patients' clinical microbiological data were collected correlated outcome.A total 27 detected from 13 tertiary care hospitals. About 78% 89% patients had...
Aspergillus is the causative agent of human diseases ranging from asthma to invasive infection. Genetic and environmental factors are crucial in regulating interaction between host Aspergillus. The role played by enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which catalyzes first rate-limiting step tryptophan catabolism along kynurenine pathway, increasingly being recognized, but whether how genetic variation IDO1 influences risk aspergillosis susceptible patients incompletely understood. In...
The ability to predict invasive fungal infections (IFI) in patients with hematological malignancies is fundamental for successful therapy. Although gut dysbiosis known occur patients, whether airway also contributes the risk of IFI has not been investigated. Nasal and oropharyngeal swabs were collected functional microbiota characterization 173 recruited a multicenter, prospective, observational study stratified according developing IFI. A lower microbial richness evenness found pharyngeal...
Abstract Invasive fungal diseases (IFDs) remain a major clinical issue in patients with hematological malignancies (HMs). To confirm the efficacy and safety of new azole isavuconazole (ISV) care setting, we planned multicenter retrospective study; collected data on all possible/probable/proven IFDs HMs treated ISV 17 centers. Between July 2016 November 2018, 128 were enrolled, 122 fully evaluable. was employed as 1 st line therapy 43 (35%) subsequent 79 (65%) patients. The response rate...
Summary We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated ibrutinib and idelalisib clinical practice. Overall, 108 of (29·8%) developed infections, for a total 152 events. Clinically defined (CDI) were 49·3% (75/152) microbiologically (MDI) 50·7% (77/152). Among 250 ibrutinib, 28·8% (72/250) experienced one or more 104 episodes. MDI 49% (51/104). Bacterial 66·7% (34/51), viral 19·6% (10/51) invasive fungal diseases (IFD) 13·7%...
It is becoming increasingly clear that the communities of microorganisms populate surfaces exposed to external environment, termed microbiota, are key players in regulation pathogen-host cross talk affecting onset as well outcome infectious diseases. We have performed a multicenter, prospective, observational study which nasal and oropharyngeal swabs were collected for microbiota predicting risk invasive fungal infections (IFIs) patients with hematological malignancies. Here, we demonstrate...
We evaluated the incidence of proven/probable invasive aspergillosis (IA) and role antifungal prophylaxis (AP) in a 'real-life' setting patients with AML receiving intensive consolidation therapy.Cases IA, observed during adult/paediatric between 2011 2015, were retrospectively collected multicentre Italian study.Of 2588 patients, 56 (2.2%) developed IA [43 probable (1.7%) 13 proven (0.5%)]. was diagnosed 34 1137 (2.9%) no AP 22 1451 (1.5%) who given (P = 0.01). Number-needed-to-treat...
Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies.HM proven (Magnusiomyces capitatus) M. capitatus or clavatus) clavatus (formerly Saprochaete capitata clavata) infection diagnosed between January 2010 December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group FungiScope (Global...
In the last 10 years, new agents became available for treatment of lymphoproliferative disorders. A number monoclonal antibodies and molecular targeted are now used in clinical practice. ...
In patients with relapsed/refractory acute myeloid leukaemia (R/R AML) who received salvage chemotherapy, limited and not updated studies explored the incidence of invasive aspergillosis (IA) role antifungal prophylaxis (AP). The aims this multicentre retrospective 'SEIFEM 2016-B' study were as follows: (1) to evaluate current rate outcome proven/probable IA (2) assess efficacy AP, in a large 'real life' series patient R/R AML submitted chemotherapy.Of 2250 patients, total 74 cases (5.1%)...
Concern has emerged about the prevalence of second cancers among patients with hairy cell leukemia (HCL) treated purine analogs. We investigated 513 HCL cladribine over last 30 years at 18 Italian centers and calculated their standardized incidence ratios (SIRs). identified 24 a cancer diagnosed median time from treatment 59.9 months (range: 9.2-169.7 months). All solid neoplasms presented limited-stage disease, except four cases locally advanced cancer; multiple myeloma had smoldering while...
Background: Isavuconazole (ISV) has been reported as safe and effective in the SECURE trial (Maertens 2016). Aims: To confirm efficacy safety of ISV hematological patients a clinical care setting. Methods: We planned multicenter retrospective study, collecting all cases invasive fungal infections (IFI) occurring (pts) treated with 17 Centers between Jul‐16 Nov‐18. IFI were categorized possible (PS), probable (PB) or proven (PV) according to EORTC/MSG criteria. The impact age, gender, type...